Annexon 

Yahoo Finance • last month

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated ne... Full story

Yahoo Finance • last month

Annexon Biosciences GAAP EPS of -$0.34 beats by $0.03

* Annexon Biosciences press release [https://seekingalpha.com/pr/20201908-annexon-reports-second-quarter-2025-financial-results-portfolio-progress-and-key-anticipated] (NASDAQ:ANNX [https://seekingalpha.com/symbol/ANNX]): Q2 GAAP EPS of... Full story

Yahoo Finance • 2 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Scienc... Full story

Yahoo Finance • 3 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Progra... Full story

Yahoo Finance • 4 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neu... Full story

Yahoo Finance • 4 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster... Full story

Yahoo Finance • 4 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neu... Full story

Yahoo Finance • 6 months ago

Why Annexon Inc. (ANNX) Went Down On Thursday?

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Annexon Inc. (NASDAQ:ANNX) stands against other stocks that fall behind amid market optimism. Wall Street’s... Full story

Yahoo Finance • 6 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers calle... Full story

Yahoo Finance • 6 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points Educational Symposium Focuses on Adva... Full story

Yahoo Finance • last year

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure... Full story

Yahoo Finance • last year

10 Buy-Rated Stocks with Latest Insider Purchases

In this article, we will take a detailed look at the 10 Buy-Rated Stocks with Latest Insider Purchases. For a quick overview of such stocks, read our article5 Buy-Rated Stocks with Latest Insider Purchases. Insider trading and its relatio... Full story

Yahoo Finance • 2 years ago

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Annexon Biosciences Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled Trial Supporting a... Full story

Yahoo Finance • 2 years ago

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Annexon Biosciences Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across Cohorts with No S... Full story

Yahoo Finance • 2 years ago

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related dis... Full story

Yahoo Finance • 2 years ago

Here's Why Annexon (NASDAQ:ANNX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said... Full story

Yahoo Finance • 2 years ago

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track f... Full story

Yahoo Finance • 2 years ago

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devasting inflammatory-related diseas... Full story

Yahoo Finance • 2 years ago

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy ANX007 is the First Therapeutic Candidate to Receive PRIME Designation by the EMA... Full story

Yahoo Finance • 2 years ago

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company’s Third Successfully Executed Clinical Study in... Full story